Lakewood, Colo. and Taipei, Taiwan, May 13, 2026 —Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions, and Steminent Biotherapeutics have entered into a strategic collaboration to accelerate late-stage manufacturing readiness for mesenchymal stem cell (MSC) therapies, addressing one of the key barriers to clinical scale-up and commercialization in regenerative medicine. The collaboration centers on optimizing automated cell expansion for clinical development and future commercial production of Steminent’s late-stage MSC-based therapy.

Few MSC therapies have been approved anywhere in the world, and global adoption has remained limited.1  One of the major challenges to broad commercialization has been effective transitioning from manual to automated manufacturing. This collaboration is intended to improve consistency, scalability and efficiency of MSC manufacturing using Terumo BCT’s Quantum Flex™ Automated Cell Expansion System, reducing reliance on manual processes. Terumo BCT will lead development of a scalable production workflow that is designed to support batch-to-batch consistency and process robustness that is aligned with Steminent’s goals. This workflow will be transferred to Steminent for continued advancement.

“Collaborating with Terumo BCT allows us to strengthen our manufacturing foundation with processes designed for late-stage development and beyond,” said Ling-Mei Wang, Chairperson of Steminent. “This work supports our MSC clinical program’s next step, scaling for late-stage trials and eventual commercialization across multiple regions.”

Upon successful completion of development milestones, Steminent plans to expand usage of Quantum Flex, leveraging the system to support broader clinical translation and commercialization plans.

This collaboration aligns with Terumo BCT’s APAC Ecosystem Blueprint — a practical, collaborative framework designed to support cell and gene therapy developers in the Asia-Pacific region as they transition from early development to scalable, repeatable manufacturing and delivery.

1. Fernández-Garza LE, Barrera-Barrera SA, Barrera-Saldaña HA. Mesenchymal stem cell therapies approved by regulatory agencies around the world. Pharmaceuticals (Basel). 2023;16(9):1334. doi: 10.3390/ph16091334

2. Quantum Flex™ is either a registered trademark or trademark of Terumo BCT, Inc. in the United States and/or other countries. See TerumoBCT.com/trademarks for details.

3. Products and services are available in selected areas subject to regulatory approval in each country.